4.64

3.73% -0.18

After Hours: 4.64

Rocket Pharmaceuticals Inc (RCKT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Rocket Pharmaceuticals Inc stock is traded at $4.64, with a volume of 3.68M. It is down -3.73% in the last 24 hours and up +54.67% over the past month. Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Previous Close:

$4.82

Open:

$4.66

24h Volume:

3.68M

Relative Volume:

1.63

Market Cap:

$502.15M

Revenue:

Net Income/Loss:

$-240.91M

P/E Ratio:

-2.0644

EPS:

-2.2476

Net Cash Flow:

$-202.83M

1W Performance:

+2.43%

1M Performance:

+54.67%

6M Performance:

+41.46%

1Y Performance:

-49.62%

1-Day Range:

$4.59

$4.76

1-Week Range:

$4.53

$5.3399

52-Week Range:

$2.19

$9.26

Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile

Name

Rocket Pharmaceuticals Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

646-440-9100

Address

350 FIFTH AVENUE, NEW YORK, NY

Employee

299

Twitter

@rocketpharma

Next Earnings Date

2024-11-04

Latest SEC Filings

RCKT's Discussions on Twitter

Compare RCKT vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RCKT Rocket Pharmaceuticals Inc	4.64	521.63M	0	-240.91M	-202.83M	-2.2476
VRTX Vertex Pharmaceuticals Inc	460.82	121.40B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	764.93	83.25B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	728.11	46.39B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	320.51	43.41B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	292.94	33.09B	5.36B	287.73M	924.18M	2.5229

Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-18-25	Downgrade	JP Morgan	Neutral → Underweight
Aug-20-25	Upgrade	BofA Securities	Neutral → Buy
Jul-25-25	Downgrade	BofA Securities	Buy → Neutral
May-30-25	Downgrade	Evercore ISI	Outperform → In-line
May-28-25	Downgrade	Goldman	Neutral → Sell
May-28-25	Downgrade	JP Morgan	Overweight → Neutral
May-28-25	Downgrade	Jefferies	Buy → Hold
May-28-25	Downgrade	Leerink Partners	Outperform → Market Perform
May-28-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-27-25	Downgrade	Needham	Buy → Hold
May-27-25	Downgrade	TD Cowen	Buy → Hold
Mar-12-25	Initiated	BMO Capital Markets	Outperform
Dec-30-24	Initiated	Wedbush	Outperform
Dec-18-24	Initiated	Jefferies	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Apr-02-24	Initiated	Goldman	Neutral
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Feb-01-23	Initiated	Morgan Stanley	Overweight
Nov-08-22	Initiated	Canaccord Genuity	Buy
Nov-01-22	Initiated	BTIG Research	Buy
Jul-08-22	Initiated	Raymond James	Outperform
Oct-20-21	Resumed	Cowen	Outperform
Mar-02-21	Initiated	Stifel	Buy
Feb-18-21	Initiated	Needham	Buy
Dec-16-20	Initiated	UBS	Buy
Dec-08-20	Downgrade	Oppenheimer	Outperform → Perform
Jul-02-20	Initiated	JP Morgan	Overweight
Jun-25-20	Resumed	BofA/Merrill	Buy
Jun-01-20	Resumed	Oppenheimer	Outperform
Nov-06-19	Initiated	Chardan Capital Markets	Buy
Sep-26-19	Initiated	Piper Jaffray	Overweight
Apr-23-19	Initiated	Robert W. Baird	Outperform
Mar-15-19	Initiated	BofA/Merrill	Buy
Feb-05-19	Initiated	Oppenheimer	Outperform
Sep-13-18	Initiated	Ladenburg Thalmann	Buy
Jul-10-18	Initiated	William Blair	Outperform

View All

Rocket Pharmaceuticals Inc Stock (RCKT) Latest News

Mar 03, 2026

Rocket gene therapy among at least 7 PDUFA dates at FDA in March - biocentury.com

Mar 03, 2026

Wedbush sees Rocket Pharmaceuticals as significantly undervalued as cardiac gene therapy pipeline advances - Yahoo! Finance Canada

Mar 03, 2026

Mar 02, 2026

Rocket Pharmaceuticals (NASDAQ: RCKT) files $400M shelf to raise capital - Stock Titan

Mar 02, 2026

Goldman Sachs Maintains 'Sell' Rating on RCKT, Raises Price Targ - GuruFocus

Mar 02, 2026

The Goldman Sachs Group Forecasts Strong Price Appreciation for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock - MarketBeat

Mar 02, 2026

Rocket Pharmaceuticals: Advancing Gene Therapy Pipeline and High-Confidence KRESLADI Approval Drive Buy Rating - TipRanks

Mar 02, 2026

Brokers Set Expectations for RCKT FY2026 Earnings - MarketBeat

Mar 02, 2026

Mar 01, 2026

Chart Watch: Is Rocket Pharmaceuticals Inc showing insider buying2025 Market Outlook & Weekly Breakout Watchlists - baoquankhu1.vn

Mar 01, 2026

Feb 28, 2026

Lifesci Capital Upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) to Strong-Buy - MarketBeat

Feb 28, 2026

Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded to "Hold" at Wall Street Zen - MarketBeat

Feb 28, 2026